Compare XFLT & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XFLT | LRMR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.5M | 253.5M |
| IPO Year | 2017 | 2014 |
| Metric | XFLT | LRMR |
|---|---|---|
| Price | $16.17 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $14.40 |
| AVG Volume (30 Days) | 119.9K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 14.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.02 | $1.92 |
| 52 Week High | $19.63 | $6.42 |
| Indicator | XFLT | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 15.81 | 44.11 |
| Support Level | $3.05 | $1.92 |
| Resistance Level | $19.53 | $3.76 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 10.08 | 68.71 |
XAI Octagon Floating Rate & Alternative Income Trust is a diversified, closed-end management investment company which invests in a dynamically managed portfolio of floating-rate credit instruments and other structured credit investments within the private markets. The Trust's investment objective is to seek attractive total return with an emphasis on income generation across multiple stages of the credit cycle.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.